Eli Lilly and Company vs Novo Nordisk A/S — Stock Comparison
Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Eli Lilly and Company clearly outscores Novo Nordisk A/S on Q·Score (7.8 vs 6.3 out of 10), led by Growth (9.8 vs 3.8) and Sentiment (7.9 vs 4). Novo Nordisk A/S scores higher on Quality, reflecting stronger profitability and returns. Analyst consensus targets imply greater upside for LLY (+5.5%) than for NVO (+1.0%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Earnings growing 26% year-over-year on 48% revenue growth.
High-quality business with 60% return on equity and 35% profit margins.
⚠ earnings contracting 21% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
LLY vs NVO: which stock scores better overall?
Based on Q·Score, Eli Lilly and Company (LLY) scores 7.8/10 versus Novo Nordisk A/S (NVO) at 6.3/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: LLY or NVO?
Eli Lilly and Company (LLY) scores higher on Growth (9.8/10 vs 3.8/10). Eli Lilly and Company reports revenue growth (47.7% YoY) while Novo Nordisk A/S reports (2.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is LLY or NVO more attractively valued?
Novo Nordisk A/S (NVO) scores higher on Valuation (6.5/10 vs 6.3/10). LLY trades at 26.4× P/E versus NVO at 13.6×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about LLY vs NVO?
There are 29 analysts covering LLY with a consensus price target of $1315.04, and 12 analysts covering NVO with a consensus target of $47.39. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: LLY or NVO?
Novo Nordisk A/S (NVO) scores higher on Quality (10/10 vs 9/10). Net profit margin: LLY at 33.5%, NVO at 35.3%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: LLY or NVO?
Novo Nordisk A/S (NVO) scores higher on Financial Health (5.9/10 vs 5.5/10). Market beta: LLY at 0.51, NVO at 0.35. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of LLY and NVO?
Eli Lilly and Company (LLY) has a market capitalisation of $1.11T, while Novo Nordisk A/S (NVO) has a market cap of $207.5B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do LLY or NVO pay dividends?
LLY pays a dividend yield of 0.55%, while NVO pays a dividend yield of 3.83%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →